Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 20, 2026, 8:19 AM EDT
Not yet recruiting Not applicable Interventional

Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients

NCT06874101
View directory record Official record
Conditions
COPD, COPD - Chronic Obstructive Pulmonary Disease
Interventions
Activated ROAM System with User Feedback, Sham Comparator
Device
Lead sponsor
Barron Associates, Inc.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study

NCT03449667
View directory record Official record
Conditions
Post-Amputation Phantom Limb Pain
Interventions
Cryoneurolysis, Sham Comparator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Palo Alto, California • San Diego, California • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 20, 2026, 8:19 AM EDT
Suspended Phase 3 Interventional

Investigational Study of Delayed Release Metformin

NCT04854512
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Drug
Lead sponsor
Anji Pharma
Industry
Eligibility
18 Years to 100 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder

NCT01090713
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
lisdexamfetamine, Placebo control
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

NCT07400718
View directory record Official record
Conditions
Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions
AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device
Device
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Drug · Other
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 20, 2026, 8:19 AM EDT
Recruiting Phase 4 Interventional

Buspirone for Anxiety in Autistic Youth

NCT07439042
View directory record Official record
Conditions
Anxiety, Autism Spectrum Disorder
Interventions
buspirone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucel, Active Comparator Option
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

NCT00940602
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deferasirox, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 20, 2026, 8:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 20, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking

NCT07055217
View directory record Official record
Conditions
Repetitive Negative Thinking, Neurofeedback
Interventions
Mindfulness Training, Mindfulness-based Neurofeedback (Real mbNF), Sham mindfulness-based neurofeedback (Sham mbNF)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

NCT01911390
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bean powder, Rice bran, Control arm, Bean powder and rice bran
Dietary Supplement
Lead sponsor
Poudre Valley Health System
Other
Eligibility
8 Years to 13 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

NCT05844735
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo, Ciprofloxacin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 20, 2026, 8:19 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Quadratus Lumborum Block for Total Hip Arthroplasty

NCT05247255
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Active Comparator, Placebo Comparator
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

NCT05579691
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological · Other
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 20, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Breast Cancer, Reasoning, and Activity Intervention

NCT04816006
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Interventions
Aerobic Exercise Training, Health Education (Active comparator)
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community

NCT06608797
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Learning and memory training, Sham Comparator
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
19 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 20, 2026, 8:19 AM EDT
Terminated Not applicable Interventional Results available

Cognitive Enhancement Through Computerized Training

NCT04244032
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Working Memory Training, Inhibitory Control Training, Bias Modification Training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
25 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 8:19 AM EDT
Terminated Not applicable Interventional Results available

Feasibility and Acceptability of Stress Induction, Physiological Data Collection, and Mindfulness-Based Stress Reduction Among Combat Veterans With PTSD

NCT05938816
View directory record Official record
Conditions
Ptsd
Interventions
Mindfulness-Based Stress Reduction (MBSR), Health and Wellness Education (HWE)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 20, 2026, 8:19 AM EDT
Completed Phase 1 Interventional

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

NCT06714955
View directory record Official record
Conditions
Non-diabetic Overweight or Obese
Interventions
Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 20, 2026, 8:19 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

NCT01890889
View directory record Official record
Conditions
Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions
Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 20, 2026, 8:19 AM EDT